TDMS Study 05025-01 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
ETHYLENE GLYCOL
NTP Experiment-Test: 05025-01 Report: PEIRPT05
Study Type: CHRONIC Date: 09/04/94
Route: DOSED FEED Time: 06:04:43
Facility: Southern Research Institute
Chemical CAS #: 107-21-1
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05025-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENE GLYCOL Date: 09/04/94
Route: DOSED FEED Time: 06:04:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 1.25% 2.5% 5.0%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 9 10
Early Deaths
Moribund 9 9 12 12
Dead 8 11 9 1
Survivors
Terminal Sacrifice 33 30 30 37
Animals Examined Microscopically 50 50 51 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (20) (21) (50)
Gallbladder (48) (18) (21) (49)
Intestine Large, Cecum (48) (19) (16) (50)
Intestine Large, Colon (49) (19) (19) (50)
Sarcoma 1 (5%)
Intestine Large, Rectum (49) (19) (17) (50)
Intestine Small, Duodenum (47) (18) (17) (50)
Intestine Small, Ileum (47) (19) (16) (50)
Intestine Small, Jejunum (47) (19) (16) (50)
Liver (50) (50) (51) (50)
Adenocarcinoma, Multiple, Metastatic, Ovary 1 (2%)
Hepatocellular Carcinoma 3 (6%) 4 (8%) 6 (12%) 3 (6%)
Hepatocellular Carcinoma, Multiple, Two 1 (2%)
Hepatocellular Adenoma 8 (16%) 5 (10%) 8 (16%) 7 (14%)
Mesentery (17) (7) (15) (7)
Adenocarcinoma, Multiple, Metastatic, Ovary 1 (14%)
Sarcoma 1 (14%) 1 (14%)
Pancreas (49) (21) (22) (50)
Adenocarcinoma, Metastatic, Ovary 1 (5%)
Sarcoma 1 (5%)
Salivary Glands (49) (20) (21) (50)
Stomach, Forestomach (50) (20) (20) (50)
Stomach, Glandular (49) (20) (20) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (20) (21) (50)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05025-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENE GLYCOL Date: 09/04/94
Route: DOSED FEED Time: 06:04:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 1.25% 2.5% 5.0%
CONTROL
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (21) (21) (50)
Adrenal Gland, Medulla (48) (21) (21) (50)
Pheochromocytoma Malignant 1 (5%)
Pheochromocytoma Benign 1 (5%) 1 (5%)
Islets, Pancreatic (49) (19) (21) (50)
Adenoma 1 (5%)
Pituitary Gland (47) (22) (23) (47)
Pars Distalis, Adenoma 17 (36%) 5 (23%) 7 (30%) 16 (34%)
Pars Distalis, Carcinoma 1 (4%)
Pars Intermedia, Adenoma 1 (5%) 1 (2%)
Thyroid Gland (49) (50) (51) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (2) (1)
Sarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (25) (25) (48)
Adenocarcinoma 1 (4%)
Cystadenoma, Papillary 2 (4%) 1 (4%) 1 (4%) 4 (8%)
Teratoma NOS 1 (2%)
Oviduct (3) (4) (1)
Uterus (50) (45) (45) (50)
Adenocarcinoma 1 (2%)
Leiomyosarcoma 1 (2%)
Endometrium, Polyp Stromal 3 (6%) 3 (7%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (20) (21) (50)
Lymph Node (50) (24) (22) (50)
Mediastinal, Adenocarcinoma, Metastatic,
Ovary 1 (4%)
Lymph Node, Mandibular (43) (21) (20) (49)
Spleen (49) (29) (28) (50)
Hemangiosarcoma 1 (4%)
Thymus (47) (19) (19) (47)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05025-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENE GLYCOL Date: 09/04/94
Route: DOSED FEED Time: 06:04:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 1.25% 2.5% 5.0%
CONTROL
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (20) (21) (50)
Adenoacanthoma 1 (2%)
Adenocarcinoma 1 (2%) 1 (5%)
Skin (49) (43) (40) (50)
Subcutaneous Tissue, Fibrosarcoma 2 (5%)
Subcutaneous Tissue, Hemangiosarcoma 1 (3%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (20) (21) (50)
Osteosarcoma 1 (5%) 1 (5%)
Skeletal Muscle (2) (2) (2) (1)
Osteosarcoma, Metastatic, Bone 1 (50%)
Abdominal, Sarcoma 1 (100%)
Neck, Sarcoma 1 (50%)
Thoracic, Sarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (49) (20) (21) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (51) (50)
Adenocarcinoma, Multiple, Metastatic,
Greater Than Five, Ovary 1 (2%)
Alveolar/Bronchiolar Adenoma 4 (8%) 4 (8%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (4%) 2 (4%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Greater Than Five, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Nose (50) (20) (21) (50)
Trachea (49) (20) (21) (50)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05025-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENE GLYCOL Date: 09/04/94
Route: DOSED FEED Time: 06:04:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 1.25% 2.5% 5.0%
CONTROL
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (2) (2) (2)
Adenoma 2 (67%) 1 (50%) 1 (50%)
Carcinoma 1 (50%) 1 (50%) 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50) (50)
Osteosarcoma, Metastatic, Bone 1 (2%)
Urinary Bladder (49) (19) (21) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(51) *(50)
Lymphoma Malignant Histiocytic 2 (4%) 2 (4%) 1 (2%)
Lymphoma Malignant Lymphocytic 3 (6%) 3 (6%) 4 (8%)
Lymphoma Malignant Mixed 13 (26%) 8 (16%) 3 (6%) 6 (12%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05025-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENE GLYCOL Date: 09/04/94
Route: DOSED FEED Time: 06:04:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 1.25% 2.5% 5.0%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 39 33 31 36
Total Primary Neoplasms 56 53 49 51
Total Animals with Benign Neoplasms 29 19 19 26
Total Benign Neoplasms 33 23 24 33
Total Animals with Malignant Neoplasms 21 21 22 16
Total Malignant Neoplasms 23 30 25 17
Total Animals with Metastatic Neoplasms 2 2 2 2
Total Metastatic Neoplasm 2 6 3 2
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05025-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENE GLYCOL Date: 09/04/94
Route: DOSED FEED Time: 06:04:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.625% 1.25% 2.5%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 6 6 6 6
Early Deaths
Dead 15 8 11 16
Moribund 10 14 11 15
Survivors
Terminal Sacrifice 29 32 32 23
Animals Examined Microscopically 54 54 54 54
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (51) (19) (16) (48)
Sarcoma 1 (2%)
Intestine Small, Duodenum (53) (20) (18) (46)
Polyp Adenomatous 1 (5%)
Intestine Small, Ileum (53) (17) (17) (45)
Intestine Small, Jejunum (54) (18) (19) (50)
Polyp Adenomatous 2 (4%) 1 (2%)
Liver (54) (53) (53) (54)
Cholangiocarcinoma 1 (2%)
Hemangiosarcoma, Multiple, Two 1 (2%)
Hepatocellular Carcinoma 10 (19%) 15 (28%) 10 (19%) 9 (17%)
Hepatocellular Carcinoma, Multiple, Two 1 (2%) 2 (4%)
Hepatocellular Carcinoma, Multiple, Four 1 (2%)
Hepatocellular Adenoma 9 (17%) 6 (11%) 5 (9%) 8 (15%)
Hepatocellular Adenoma, Multiple, Two 2 (4%)
Serosa, Sarcoma 1 (2%)
Mesentery (5) (3) (1) (7)
Cholangiocarcinoma, Metastatic, Liver 1 (20%)
Hemangiosarcoma 1 (20%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (33%)
Sarcoma 1 (20%)
Pancreas (54) (23) (21) (54)
Salivary Glands (53) (21) (20) (54)
Stomach, Forestomach (54) (20) (21) (54)
Mast Cell Tumor Benign 1 (2%)
Stomach, Glandular (54) (20) (21) (54)
Tooth (21) (4) (1) (18)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05025-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENE GLYCOL Date: 09/04/94
Route: DOSED FEED Time: 06:04:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.625% 1.25% 2.5%
CONTROL
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (54) (21) (22) (54)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (54) (20) (21) (54)
Adenoma 2 (4%)
Capsule, Cholangiocarcinoma, Metastatic,
Liver 1 (2%)
Capsule, Sarcoma 1 (2%)
Subcapsular, Adenoma 1 (2%) 3 (6%)
Subcapsular, Adenoma, Multiple 1 (2%)
Adrenal Gland, Medulla (54) (21) (21) (53)
Pheochromocytoma Benign 1 (2%) 1 (5%)
Pituitary Gland (52) (21) (17) (49)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (53) (53) (54) (53)
Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (2)
Sarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (54) (21) (22) (54)
Hemangioma 1 (2%)
Prostate (53) (20) (22) (54)
Sarcoma 1 (2%)
Seminal Vesicle (52) (23) (23) (54)
Sarcoma 1 (2%)
Testes (54) (22) (22) (54)
Interstitial Cell, Adenoma 1 (5%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05025-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENE GLYCOL Date: 09/04/94
Route: DOSED FEED Time: 06:04:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.625% 1.25% 2.5%
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (54) (21) (22) (54)
Hemangiosarcoma 1 (2%)
Lymph Node (54) (33) (27) (54)
Lymph Node, Mandibular (45) (19) (17) (51)
Spleen (54) (53) (53) (53)
Hemangiosarcoma 2 (4%) 1 (2%)
Thymus (53) (19) (19) (51)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (54) (45) (43) (54)
Basosquamous Tumor Benign 1 (2%)
Mast Cell Tumor Benign 1 (2%)
Subcutaneous Tissue, Fibroma 2 (4%) 2 (4%) 1 (2%) 2 (4%)
Subcutaneous Tissue, Fibrosarcoma 3 (6%) 8 (18%) 5 (12%) 1 (2%)
Subcutaneous Tissue, Fibrosarcoma, Multifocal 1 (2%)
Subcutaneous Tissue, Fibrosarcoma,
Metastatic, Skin 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 2 (4%)
Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%)
Subcutaneous Tissue, Schwannoma NOS 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1)
Diaphragm, Cholangiocarcinoma, Metastatic,
Liver 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (54) (25) (32) (54)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Alveolar/Bronchiolar Adenoma 6 (11%) 2 (8%) 7 (22%) 3 (6%)
Alveolar/Bronchiolar Adenoma, Multiple, Two 1 (3%)
Alveolar/Bronchiolar Adenoma, Multiple,
Page 9
NTP Experiment-Test: 05025-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENE GLYCOL Date: 09/04/94
Route: DOSED FEED Time: 06:04:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.625% 1.25% 2.5%
CONTROL
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Greater Than Five 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (4%) 2 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple, Two 1 (4%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibrosarcoma, Multiple, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Four, Liver 1 (3%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Five, Liver 1 (4%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Greater Than Five, Liver 1 (3%)
Mediastinum, Fibrosarcoma, Metastatic, Skin 1 (2%)
Mediastinum, Hepatocellular Carcinoma,
Metastatic, Liver 1 (3%)
Pleura, Fibrosarcoma, Multiple, Metastatic,
Skin 1 (2%)
Nose (54) (21) (21) (54)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (3)
Adenoma 2 (100%) 2 (67%)
Carcinoma 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (54) (53) (53) (54)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Capsule, Sarcoma 1 (2%)
Renal Tubule, Adenoma 1 (2%) 1 (2%)
Urinary Bladder (53) (53) (53) (54)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(54) *(54) *(54) *(54)
Histiocytic Sarcoma 2 (4%)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%)
Lymphoma Malignant Mixed 6 (11%) 3 (6%) 5 (9%) 6 (11%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05025-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENE GLYCOL Date: 09/04/94
Route: DOSED FEED Time: 06:04:43
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.625% 1.25% 2.5%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 34 36 31 33
Total Primary Neoplasms 67 46 44 47
Total Animals with Benign Neoplasms 17 11 13 19
Total Benign Neoplasms 29 14 17 24
Total Animals with Malignant Neoplasms 22 28 23 20
Total Malignant Neoplasms 38 31 27 23
Total Animals with Metastatic Neoplasms 2 2 2 1
Total Metastatic Neoplasm 7 3 4 4
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------